Return-to-activity rates cited in published case series range from 55–85%, depending on injury severity and pre-treatment duration of symptoms. Acute tears (≤3 months) tend to show better outcomes than chronic tendinopathy (>1 year). In the absence of blinded controls, distinguishing spontaneous healing from therapy-induced improvement remains difficult; many athletes also undergo structured physiotherapy concurrently.
The tendon-injury cell-therapy landscape encompasses 22 completed trials and 1 actively recruiting study. Most involve placental MSC injections or exosome preparations administered directly into the tendon lesion under ultrasound guidance. Trial cohorts typically include both acute partial tears and chronic degenerative tendinopathy. Imaging outcomes (ultrasound, MRI) in small studies show improved fibre continuity and reduced fluid signal in approximately 50–70% of treated tendons. Functional metrics (strength, pain reduction, return-to-activity) vary by trial; some report 60–80% of athletes returning to sport within 6–12 months, though untreated controls are rarely present for comparison.
Съм ли кандидат? → · Tendon & Sports Injuries: full overview → · Цена Наранявания на сухожилия и спортни наранявания → · Cost →
Медицински преглед от редакционния екип на StemCellAtlas с Dr Tymur Lukyanenko (Orthopaedic Traumatologist · 20+ yrs clinical, 15+ yrs cell therapy) на партньорската клиника Stem Plus (София), спрямо ISSCR, FDA и EMA указания. Educational information, not medical advice; figures indicative.
GMP-сертифицирана регенеративна медицина в сърцето на ЕС — от 3 000–8 000 €, част от цените в САЩ или Германия. Персонализирани протоколи за пациенти от над 50 държави.
Безплатна медицинска оценка